Giving health coverage to people with HIV seems to increase viral suppression. But the future of health coverage gains in the U.S. is uncertain.
Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.
New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Best Practices for Most Vulnerable Populations: Transgender People, Adolescents, and the Recently Incarcerated
"As we think about the care cascade, we can't even test people [for HIV] to diagnose them if we can't get them in the door to a health care setting," one clinician said.
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
People in jail, who are often in the system for less time than those in prison, often receive little to no hepatitis C screening or treatment. One provider works to change this in Massachusetts.
Black Women in Atlanta Need More PrEP Access. Researchers and Advocates Are Working to Make This a Reality.
While most pre-exposure prophylaxis (PrEP) campaigns focus on gay and bisexual men, Fulton County Board of Health officials and advocates look for solutions to get PrEP to black women.
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.
If everyone living with HIV gets into care, do we have enough providers to support them? HIV doctors are proposing policy changes to address the workforce shortage.
At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.